Engineered immune cells take aim at a common cancer target in Hard-to-Treat tumors

This early study tests a new treatment called SUV2208A, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack cancer cells carrying a protein called CLDN18.2. The trial enrolls up to 18 adults with advanced solid tumors that have not responded to standard treatments. Researchers are primarily looking at safety and the right dose, while also checking how long the cells last in the body and whether they have any effect on the tumors.